Classifications

• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
  • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B5/00—Measuring for diagnostic purposes; Identification of persons
  • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
  • A61B5/021—Measuring pressure in heart or blood vessels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B5/00—Measuring for diagnostic purposes; Identification of persons
  • A61B5/48—Other medical applications
  • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B5/00—Measuring for diagnostic purposes; Identification of persons
  • A61B5/48—Other medical applications
  • A61B5/4854—Diagnosis based on concepts of alternative medicine, e.g. homeopathy or non-orthodox
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
  • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
  • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
  • G16B40/20—Supervised data analysis
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
  • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
  • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• • G—PHYSICS
  • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
  • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
  • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
  • G16H20/90—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
  • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

• the present invention relates to discover effective and safe components in herbal medication. Description of the related art.
• TCM Traditional Chinese Medicine
• TCM Traditional Chinese Medicine
• Herbals have very complex chemical compositions, even a single herb consists of hundreds unknown compounds, and TCM is composed with several or even dozens of herbals, safety and efficacy might be involved with different compounds from various herbals and their metabolites.
• Classical method to study TCM is to extract a single chemical constituents from an herbal, then analyze the activity of the ingredients one by one, in vivo or in vitro. However, the method cannot detect safety and efficacy of metabolites, nor synergistic effects among different compounds in TMC.
• the present invention is a method to identify the active ingredients of traditional Chinese medicine
• the present invention include a website to allow providers to record patients' condition, diagnosis and treatment through the website.
• the patients' data can be collected by provider to conduct statistical analysis.
• the chemical compositions of herbals can be analyzed.
• provider can conduct both internal and external tests to determine the active ingredients, and treat patients with pure effective compounds or together with combination of herbals.
• FIG. 1 Digitize TMC which provide information for safety and efficacy of herbals.
• FIG. 2 Analyze and determine effective components.
• FIG. 3 Selection Common Components among Patients with Preferred Outcome.
• FIG. 4 Discovery of effective anti -bacterial components.
• FIG. 5 Chemical analysis shows the highest concentration of W, Y, and Z in each patient.
• FIG. 6 Patients' responses and their types of biomarkers.
• FIG. 7 Classification of patients based on their response to herbals.
• a same concoction may have different results in various patients, through whom the concoction could be found safe and effective, or safe, but not effect. Doctors can analyze the results, and adjust compositions, re-treat patients to improve outcome. Practitioners can compare patients with different treatments to detect side effects of herbals. Preferred results could be announced or published, other doctors can repeat these results in the same way, which makes TMC measurable and repeatable, and transform it from experience to science. If preferred results are found, the next step is the analysis and discovery of active ingredients, the process is illustrated in FIG. 1.
• Logistic regression could be applied to remove non-significant compositions with a binary data as dependent variable
• ANCOVA could be applied for a linear dependent variable
• survival analysis will be used with for long-term study.
• Clinical improvement will be dependent variable
• chemical compositions will be dependent variables.
• the synthesized compound can be used alone to treat the patients. If some patients have preferred results, these compounds are proved to effective and can be used alone clinically.
• Case 1 Discovery effective components to treat hypertension from herbals.
• a TCM doctor treats hypertension with concoction composed by A, B, C, D, E herbals, twenty patients were treated. Initially, all patients have high blood pressure and without other disease. These patients are treated and come back to the clinic once every three days. After two weeks, blood pressure among ten patients becomes normal; there is no change in blood pressure in the other ten patients. Blood collection is done at times at 0, 0.5, 1, 2, 4, 8, 12, 24 hours after the treatment.
• Y is a known compound and can be synthesized, and Z is unknown compound.
• W is a compound in herbal A
• Y is a compound in the B
• Z is neither present in A, B, C, E herbal, nor present in the mixture of A, B, C, E, therefore, Z must a metabolite of either A, or B, or C, or E, a vivo metabolite vivo.
• the compounds W, Y, Z are synthesized and are used to treat 7 patients (PI to P7) every day, their blood pressure are checked after 2 weeks.
• biomarkers for ten patients with a good response is HHH.
• these biomarker should be checked first; if the biomarker is AAA or CCC, or HHH, the compound W, Y, Z can be applied for the treatment, patients with biomarkers BBB, DDD, EEE should not be treated with these compounds as explained in FIG. 3, in the table in FIG. 6 and in the table in FIG 7.
• Embodiment 2 Discovery anti -bacterial components in herbals, Doctors use herbals to treat patients with E. coli septicemia, there are ten patients treated with the first concoction. Blood collection are done at time points 0, .5, 1, 2, 4, 8, 12, and 24 hours after patients take the concoction. In vitro collection tests are done, and the result is as follows:
• the mean of the colony was 52 with standard deviation (S.D) 11; after 24 hours of the treatment, the number of the colony was 222 with S.D. 35. the first concoction in -effective. The result demonstrates the concoction ineffective.
• the mean was 522 with S.D 41; after 24 hours of the treatment, the mean was 15 with S.D. 3. the 2nd concoction is effective.
• the C3-C4 are tested on the in vitro Petri -dish and found that they have prominent activities for killing bacteria.
• the peak concentration can be determined by measuring the blood samples collected at different times from these patients, the highest concentration are obtained by measuring blood samples at different times, and proper dosage for C1-C4 can be decided. There is no observation of side effects in these patients, and no reports of side effects from hundred years practice with these herbals
• C3-C4 non-effective or with significant adverse effect, and chemical databases are recheck, the structures of C1-C2 are also known and are commercially available.
• the highest concentration are obtained by measuring blood samples at different times, and proper dosage for C1-C4 can be decided.
• Vitro validity tests are done with C1-C4 without issues.
• the volunteers for safety testing are performed, and there is no observation of side effects in these patients, and no reports of side effects from hundred years practice with these herbals.
• C1-C4 can be done in volunteers for safety and efficacy. The preferred reaction are observed, and no significant side effects seen, the C1-C4 drug can treat the disease, the whole process is shown in FIG. 4.
• BP blood pressure
• a patient produce preferred response to herbal treatment some components must exist for the response, they could be different components existed in the herbs, or reaction components from different herbals, or metabolic compounds within human body.
• Patients with preferred response should have reaction mechanisms, such as receptors, chain reaction, enzyme subtypes, and so on.
• reaction mechanisms such as receptors, chain reaction, enzyme subtypes, and so on.
• they can be divided into three categories: A, B, C. Referring to FIG. 7 this is the table to show the classification of patients based on their response to herbals. Types A and B patients can be treated with by these herbals, whereas type C patients cannot be, as these patients lack necessary reaction chain for the herbals; these types of patients can be identified by scientific methods. All information is hypothetical ones.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medical Informatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Physics & Mathematics (AREA)
• Epidemiology (AREA)
• Biophysics (AREA)
• Primary Health Care (AREA)
• Data Mining & Analysis (AREA)
• Animal Behavior & Ethology (AREA)
• Pathology (AREA)
• Surgery (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Heart & Thoracic Surgery (AREA)
• Biomedical Technology (AREA)
• Artificial Intelligence (AREA)
• Spectroscopy & Molecular Physics (AREA)
• Computer Vision & Pattern Recognition (AREA)
• Alternative & Traditional Medicine (AREA)
• Databases & Information Systems (AREA)
• Evolutionary Computation (AREA)
• Software Systems (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Bioinformatics & Computational Biology (AREA)
• Biotechnology (AREA)
• Evolutionary Biology (AREA)
• Bioethics (AREA)
• Theoretical Computer Science (AREA)
• Cardiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Vascular Medicine (AREA)
• Physiology (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medical Treatment And Welfare Office Work (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (4)

Applications Claiming Priority (4)

Publications (2)

Family

ID=55525998

Family Applications (1)

Country Status (6)

Families Citing this family (2)

Citations (2)

Family Cites Families (8)

• 2015
  • 2015-09-26 US US14/866,924 patent/US20160085941A1/en not_active Abandoned
• 2016
  • 2016-03-03 AU AU2016233772A patent/AU2016233772A1/en not_active Abandoned
  • 2016-03-03 JP JP2017548209A patent/JP2018508084A/ja active Pending
  • 2016-03-03 EP EP16765419.3A patent/EP3268926A4/en not_active Withdrawn
  • 2016-03-03 CN CN201680003852.3A patent/CN108351328A/zh active Pending
  • 2016-03-03 WO PCT/US2016/020789 patent/WO2016148936A1/en not_active Ceased

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events